Granada Hills, California--(Newsfile Corp. - June 25, 2021) - Pervasip Corp. (OTC Pink: PVSP) (the "Company") is pleased to announce the hiring of top medical staff for its minority owned unit Kaiyon Biotech Inc. ("Kaiyon"). The Company recently announced its purchase of 5% of Kaiyon, which is a U.S. research and development company working in South Korea. Kaiyon has now established a consortium of experienced doctors, professors, and researchers (the "Team") dedicated to improving mankind's debilitating physical and mental ailments using psilocybin and CBD compounds.
Kaiyon is working with universities in South Korea to facilitate research and development of a commercialized psilocybin/CBD compound. The Team has studied CBD compounds for more than 5 years and is prepared to commence research adding psilocybin to the formulations.
According to Paul Riss, CEO of Pervasip Corp., "We purchased this asset to help us join the race to bring psilocybin and CBD to the market internationally and make deals to further the Company's dedication to bringing holistic medicines to market for debilitating diseases and ailments. Valuations in this industry are growing fast and we believe that Kaiyon's relationships with universities and labs in South Korea put us in a position to build partnerships internationally."
"Pervasip's attorney prepared employment contracts and strategic advisor agreements for the Team," continued Mr. Riss. "We are enthusiastic about the talent that has signed with Kaiyon, which includes research professors, biochemists and a synthetic compound geneticist. As early as next week, we plan to disclose the Team on Kaiyon's website."
Kaiyon's CEO is a research professor at the Department of Marine Bioscience and Technology at the Gangneung-Wonju National University. He has over 90 Science Citation Index international research papers published. One of his current projects is the development of a cancer drug using natural products, small molecular compounds and anti-bodies.
About Pervasip Corp.
Pervasip Corp. is a developer of companies and technologies in high value emerging markets. In addition to its ownership percentage in the Kaiyon entity, which focuses on CBD and psilocybin, Pervasip is currently pursuing the acquisition of Artizen Corporation, which generates revenues by providing leasing, licensing, management, staffing, and supplies to cannabis production facilities.
Please email Investor Relations with any questions at info@pervasip.net or call 855-464-2535 extension 1.
The information contained herein includes forward-looking statements. These statements relate to future events or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include those that use forward-looking terminology, such as the words "anticipate," "believe," "estimate," "expect," "intend," "may," "hope'" "project," "plan," "will," "shall," "should," and similar expressions, including when used in the negative. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/88637
